LLY

805.71

-1.45%↓

UNH

556.95

-1.68%↓

JNJ

158.12

-1.16%↓

NVO

109.92

-1.81%↓

ABBV

200.71

-1.24%↓

LLY

805.71

-1.45%↓

UNH

556.95

-1.68%↓

JNJ

158.12

-1.16%↓

NVO

109.92

-1.81%↓

ABBV

200.71

-1.24%↓

LLY

805.71

-1.45%↓

UNH

556.95

-1.68%↓

JNJ

158.12

-1.16%↓

NVO

109.92

-1.81%↓

ABBV

200.71

-1.24%↓

LLY

805.71

-1.45%↓

UNH

556.95

-1.68%↓

JNJ

158.12

-1.16%↓

NVO

109.92

-1.81%↓

ABBV

200.71

-1.24%↓

LLY

805.71

-1.45%↓

UNH

556.95

-1.68%↓

JNJ

158.12

-1.16%↓

NVO

109.92

-1.81%↓

ABBV

200.71

-1.24%↓

Kodu・Aktsiate loetelu・Karyopharm Therapeutics Inc

Karyopharm Therapeutics Inc

Suletud

Sektor Tervishoid

0.88 -11.11

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

0.88

Max

0.94

Põhinäitajad
By Trading Economics
Müük	34M
Aktsiakasum	-0.36
Töötajad	325

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+381.11 upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	5. nov 2024

Turustatistika
By TradingEconomics
Turukapital	1.2M 154M
Eelmine avamishind	11.99
Eelmine sulgemishind	0.88

Uudiste sentiment

By Acuity

50%

167 / 390 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bullish Evidence

0.8999 / 0.9898 Toetus ja vastupanu

Karyopharm Therapeutics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

3. nov 2024, 23:05 UTC

Peamised uudised

Fitch Affirms Australia's Sovereign AAA Rating, But Warns Of Mounting Budget Risks

3. nov 2024, 21:12 UTC

Tulu

Westpac Says Annual Profit Falls 3%, Upbeat on Prospects -- Update

3. nov 2024, 20:59 UTC

Tulu

Westpac Says Annual Profit Falls 3%, Upbeat on Prospects

3. nov 2024, 23:34 UTC

Peamised uudised

Stocks Poised for Lower Open -- Barrons.com

3. nov 2024, 23:16 UTC

Peamised uudised

Tulu

Berkshire Hathway Earnings Weren't as Bad as They Looked -- Barrons.com

3. nov 2024, 22:50 UTC

Omandamised, ülevõtmised, äriostud

Santos Says Working Interest in PNG LNG Now 39.9%

3. nov 2024, 22:50 UTC

Omandamised, ülevõtmised, äriostud

Santos Says Kumul to Assume $90 Million of Project Finance Debt Associated With Stake

3. nov 2024, 22:49 UTC

Omandamised, ülevõtmised, äriostud

Santos Says Final Payment Takes Total Cash Consideration to $602 Million

3. nov 2024, 22:49 UTC

Omandamised, ülevõtmised, äriostud

Santos Receives Final $241 Million Payment From Kumul

3. nov 2024, 22:48 UTC

Omandamised, ülevõtmised, äriostud

Santos Completes Sale of 2.6% Interest in PNG LNG to Kumul Petroleum

3. nov 2024, 20:37 UTC

Tulu

Westpac FY 2024 Deposits Increased 5% to A$674 Billion

3. nov 2024, 20:37 UTC

Tulu

Westpac FY 2024 Loans Increased 4% to A$807 Billion

3. nov 2024, 20:37 UTC

Tulu

Westpac FY 2024 Impairment Charges 7 Bps of Loans

3. nov 2024, 20:37 UTC

Tulu

Westpac FY 2024 Operating Expenses A$10.94 Billion, Up 7% Excluding Notable Items

3. nov 2024, 20:36 UTC

Tulu

Westpac FY 2024 Non-Interest Income A$2.84 Billion, Down 15%

3. nov 2024, 20:35 UTC

Tulu

Westpac FY 2024 CET1 Level 2 Capital Ratio 12.5%, Up 11 Bps

3. nov 2024, 20:35 UTC

Tulu

Westpac Raises Share Buyback Program by A$1 Billion

3. nov 2024, 20:35 UTC

Tulu

Westpac Final Dividend A$0.76/Share

3. nov 2024, 20:33 UTC

Tulu

Westpac FY 2024 Net Interest Margin Down 1 Bps at 1.95%

3. nov 2024, 20:32 UTC

Tulu

Westpac FY 2024 Revenue A$21.59 Billion, Flat on FY 2023

3. nov 2024, 20:32 UTC

Tulu

Westpac FY Net Profit A$6.99 Billion, Down 3%

3. nov 2024, 18:09 UTC

Peamised uudised

Boeing Had a Big Week. This One Is Even Bigger. -- Barrons.com

3. nov 2024, 10:30 UTC

Peamised uudised

Fed Prepares Rate Cut Amid Economic Contradictions -- WSJ

3. nov 2024, 03:00 UTC

Peamised uudised

Disgraced Lebanese Central Banker Who Was a Fugitive Now Awaits His Fate -- WSJ

2. nov 2024, 13:53 UTC

Peamised uudised

Tulu

Omandamised, ülevõtmised, äriostud

Warren Buffett's Berkshire Hathaway Slashes Apple Stake Again -- Update

2. nov 2024, 13:44 UTC

Tulu

Omandamised, ülevõtmised, äriostud

Berkshire Sold 25% of Its Apple Stock in the Third Quarter -- Barrons.com

2. nov 2024, 13:00 UTC

Peamised uudised

China's EV Makers Set Sights on Latin America in Global Expansion -- WSJ

2. nov 2024, 12:58 UTC

Tulu

Omandamised, ülevõtmised, äriostud

Berkshire Sold 25% of Its Apple Stock in the Third Quarter -- Barrons.com

2. nov 2024, 12:48 UTC

Peamised uudised

Tulu

Omandamised, ülevõtmised, äriostud

Warren Buffett's Berkshire Hathaway Slashes Apple Stake Again -- WSJ

2. nov 2024, 12:32 UTC

Tulu

Berkshire Profits Fell 6% in Third Quarter. The Buybacks Are on Pause. -- Barrons.com

Võrdlus sarnastega

Hinnamuutus

Karyopharm Therapeutics Inc Prognoos

Hinnasiht

By TipRanks

381.11% tõus

12 kuu keskmine prognoos

Keskmine 4.33 USD 381.11%

Kõrge 7 USD

Madal 2 USD

Põhineb 6 Wall Streeti analüütiku instrumendi Karyopharm Therapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

6 ratings

Osta

Hoia

Müü

Põhineb 6 analüütiku instrumendi Karyopharm Therapeutics Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

0.8999 / 0.9898Toetus ja vastupanu

Recent bullish events outweigh bearish events.

Bearish events outweigh bullish events.

Sentiment

By Acuity

167 / 390 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Karyopharm Therapeutics Inc

Karyopharm Therapeutics Inc. is a commercial-stage pharmaceutical company. It is focused on the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. Its Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1 (CRM1). Its lead compound, XPOVIO (selinexor), is marketed in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). NEXPOVIO (selinexor), the brand name for XPOVIO in Europe, in combination with dexamethasone to treat adult patients with multiple myeloma. It is also developing treatments for other diseases.